Christoph Bausch
Executive VP & COODr. Christoph Bausch, PhD, MBA, serves as Executive VP of SAB Biotherapeutics, Inc. and serves as its Chief Operating Officer since May 2022 and served as Chief Science Officer since March 2017 until May 2022. Dr. Bausch is an experienced research scientist, biotech entrepreneur and business development executive who has led the successful discovery, development, and commercialization of platform technologies in the life sciences. Since September 2011, he has been the Founder and Director of Nanopore Diagnostics, a molecular diagnostic company commercializing platform sensor technology for rapid microbial diagnostics. Since October 2011, he has acted as President of Keion Group, LLC, a life science consulting firm. Dr. Bausch held several science-based business development positions prior to joining SAB, most recently for multi-billion-dollar global biorefining leader POET, LLC, where he structured strategic partnerships, prospected, and vetted new technologies and streamlined research and development activities. He also worked in both research and commercialization roles for Fortune 500 life science and high technology company Sigma-Aldrich, now MilliporeSigma. Dr. Bausch is a microbiologist by training and received his Ph.D. in Microbiology at The Ohio State University (Columbus, Ohio), completed Post-Doctoral Training at the Stowers Institute for Medical Research (Kansas City, Missouri). He holds an M.B.A. from St. Louis University (St. Louis, Missouri) and a B.A. in Biology from the University of Nebraska-Lincoln (Lincoln, Nebraska).
Positions
- Company NameSAB Biotherapeutics, Inc.Stock CodeSABSPositionExecutive VP & COOColleagues
- SJSamuel J. ReichCEO & Director
- DSDavid Scott ZaccardelliIndependent Chair of the Board
- EJEddie Joe SullivanCo-Founder, President & Director
- LTLucy ToExecutive VP & CFO
- AKAlexandra KropotovaExecutive VP & Chief Medical Officer
- DCDavid Charles LinkIndependent Vice Chairman
- EJErick J. LuceraIndependent Director
